相关实验视频

Updated: Sep 13, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

机制研究抑制EPHA2表达皮肤屏障功能受损通过gefitinib

Jiang-Yuan Zhang^1,2, Xue-Kun Nie^1,2,3, Zi-Chun Chen^1,2,3

¹Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, China.

Experimental dermatology

|July 30, 2025

概括

用于治疗非小细胞肺癌的盖菲提尼布 (gefitinib) 通过破坏皮肤屏障引起皮肤问题. 这项研究发现,以弗林A型受体2 (EPHA2) 下调是关键,恢复EPHA2可以治疗这些副作用.

科学领域:

在瘤学瘤学.
皮肤病学皮肤病学
药理学药理学是指药理学的学科.

背景情况:

格菲提尼布 (表皮生长因子受体氨酸激酶抑制剂) 对晚期非小细胞肺癌 (NSCLC) 有效.
来自gefitinib的皮肤毒性限制了其临床使用,并影响了患者的治疗结果.
了解gefitinib诱导的皮肤屏障功能障碍的机制对于开发新疗法至关重要.

研究的目的:

用网络药理学和分子对接来确定gefitinib诱导的皮肤屏障功能障碍的病因因素.
调查以弗林A型受体2 (EPHA2) 在gefitinib诱导的皮肤毒性的作用.
探索针对EPHA2.2的潜在治疗策略.

主要方法:

网络药理学和分子对接以识别关键介质.
用小鼠模型和HaCaT角质细胞来评估gefitinib的作用.
血素和欧 (HE) 染色,免疫组织化学,RT-qPCR和西布洛特试验来评估分子变化.
用一个EPHA2激动剂 (Ephrin-A1 Fc) 来测试治疗潜力.

主要成果:

网络药理学和分子对接确定了EPHA2作为一个中心调解器.
盖菲提尼布在小鼠中诱导皮肤损伤,并改变了质蛋白和质蛋白在质细胞中的表达.
盖菲提尼布抑制了EPHA2表达和角质细胞活力,同时增加了炎症标志物.
埃弗林-A1 Fc治疗改善了gefitinib诱导的皮肤损伤,并逆转了分子变化.

结论:

格菲提尼布诱导皮肤屏障功能障碍主要通过下调EPHA2.
恢复EPHA2的表达或活性可能是一个可行的治疗策略,以减轻gefitinib诱导的皮肤毒性.
这项研究提供了关于EGFR-TKI相关皮肤不良事件的机制的见解.

关键词:

在 EGFR-TKIs 的基础上.这就是EPHA2的原因.盖菲提尼布 (gefitinib) 是一种药物.网络药理学网络药理学皮肤障碍物皮肤障碍物

更多相关视频

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.

Clinical Applications of Epidermal Stem Cells

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...